Portola Pharmaceuticals Inc (NASDAQ:PTLA) saw unusually large options trading on Wednesday. Stock investors bought 2,163 put options on the stock. This represents an increase of approximately 1,960% compared to the average daily volume of 105 put options.

Shares of NASDAQ PTLA opened at $33.02 on Thursday. The company has a market capitalization of $2.31 billion, a P/E ratio of -6.59 and a beta of 2.39. Portola Pharmaceuticals has a 12-month low of $14.81 and a 12-month high of $45.60. The company has a debt-to-equity ratio of 2.25, a quick ratio of 5.01 and a current ratio of 5.12.

Portola Pharmaceuticals (NASDAQ:PTLA) last announced its quarterly earnings results on Friday, March 1st. The biopharmaceutical company reported ($1.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.11) by $0.07. The business had revenue of $15.30 million for the quarter, compared to the consensus estimate of $10.53 million. Portola Pharmaceuticals had a negative return on equity of 167.94% and a negative net margin of 872.72%. The business’s revenue was up 56.1% on a year-over-year basis. During the same quarter last year, the business posted ($1.41) EPS. On average, research analysts forecast that Portola Pharmaceuticals will post -3.92 earnings per share for the current year.

In other news, Director Hollings Renton sold 5,000 shares of Portola Pharmaceuticals stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $34.45, for a total value of $172,250.00. Following the completion of the transaction, the director now owns 14,000 shares in the company, valued at approximately $482,300. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Mardi Dier sold 40,486 shares of Portola Pharmaceuticals stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $37.39, for a total value of $1,513,771.54. Following the completion of the transaction, the chief financial officer now owns 66,733 shares of the company’s stock, valued at approximately $2,495,146.87. The disclosure for this sale can be found here. 4.60% of the stock is currently owned by company insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Parallel Advisors LLC lifted its holdings in shares of Portola Pharmaceuticals by 165.2% in the 4th quarter. Parallel Advisors LLC now owns 4,641 shares of the biopharmaceutical company’s stock worth $90,000 after purchasing an additional 2,891 shares during the last quarter. Pacer Advisors Inc. bought a new stake in shares of Portola Pharmaceuticals in the 3rd quarter worth approximately $221,000. Squarepoint Ops LLC bought a new stake in shares of Portola Pharmaceuticals in the 4th quarter worth approximately $205,000. Xact Kapitalforvaltning AB lifted its holdings in shares of Portola Pharmaceuticals by 12.5% in the 4th quarter. Xact Kapitalforvaltning AB now owns 10,788 shares of the biopharmaceutical company’s stock worth $211,000 after purchasing an additional 1,200 shares during the last quarter. Finally, Evanson Asset Management LLC lifted its holdings in shares of Portola Pharmaceuticals by 37.0% in the 4th quarter. Evanson Asset Management LLC now owns 13,700 shares of the biopharmaceutical company’s stock worth $267,000 after purchasing an additional 3,700 shares during the last quarter.

Several research analysts have recently commented on PTLA shares. BNP Paribas lifted their target price on Portola Pharmaceuticals from $30.00 to $42.00 and gave the stock a “positive” rating in a research report on Monday, March 4th. Oppenheimer set a $30.00 target price on Portola Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, January 14th. BidaskClub raised Portola Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, February 20th. Zacks Investment Research raised Portola Pharmaceuticals from a “hold” rating to a “buy” rating and set a $37.00 price target on the stock in a report on Thursday, March 21st. Finally, ValuEngine downgraded Portola Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, March 7th. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Portola Pharmaceuticals has an average rating of “Buy” and an average target price of $42.43.

COPYRIGHT VIOLATION NOTICE: “Stock Traders Buy Large Volume of Portola Pharmaceuticals Put Options (PTLA)” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another site, it was illegally copied and reposted in violation of US and international copyright & trademark laws. The correct version of this story can be accessed at https://www.thecerbatgem.com/2019/04/18/stock-traders-buy-large-volume-of-portola-pharmaceuticals-put-options-ptla.html.

Portola Pharmaceuticals Company Profile

Portola Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics that could advance the fields of thrombosis and other hematologic diseases. The company's two FDA-approved medicines are Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo), an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of VTE in adult patients hospitalized for an acute medical illness.

Recommended Story: What is a stock buyback?

Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.